Senologie - Zeitschrift für Mammadiagnostik und -therapie 2009; 6(4): 215-223
DOI: 10.1055/s-0030-1247185
Für Sie referiert und kommentiert

© Georg Thieme Verlag KG Stuttgart ˙ New York

Onkologie - Kardioprotektion beim Mammakarzinom

K. Schumacher1 , M. Muscholl2 , C. Zürn3 , E.-M. Grischke1 , T. Fehm1
  • 1Universitätsfrauenklinik Tübingen, Universitätsklinikum Tübingen
  • 2Kardiologische Praxis, Sollner Str. 65b, 81479 München
  • 3Innere Medizin III, Universitätsklinikum Tübingen
Further Information

Publication History

Publication Date:
19 January 2010 (online)

Also available at
 

Adjuvante und palliative Systemtherapien zählen zur Standardbehandlung des Mammakarzinoms. Allerdings haben einige dieser Therapien ein erhöhtes Risiko für kardiovaskuläre Nebenwirkungen, was insbesondere eine Rolle spielen kann bei älteren Patientinnen mit vorbestehenden kardiovaskulären Erkrankungen oder auch jüngeren Frauen mit kardiovaskulärer Vorbelastung, häufig resultierend aus aggressiven dosisdichten Therapieschemata. Für Therapeuten ist es essentiell, diese kardialen Risiken und Möglichkeiten der Verlaufskontrollen zu verstehen, insbesondere wenn Kombinationstherapien oder verschiedene Substanzen kurz hintereinander appliziert werden.

Literatur

  • 01 Thomssen C . AGO fdKMd . AGO-Empfehlungen Mammakarzinom. Diagnostik und Therapie - Update 2008.  Gynäkologie + Geburtshilfe. 2008;  2 38-40
    Google Scholar
  • 02 Hanrahan E O, Gonzalez-Angulo A M, Giordano S H, Rouzier R , Broglio K R, Hortobagyi G N, et al . Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.  J Clin Oncol. 2007;  25 (31) 4952-4960
    Google Scholar
  • 03 Yeh E T, Tong A T, Lenihan D J, Yusuf S W, Swafford J , Champion C , et al . Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.  Circulation. 2004;  109 (25) 3122-3131
    Google Scholar
  • 04 Ewer M S, Lippman S M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.  J Clin Oncol. 2005;  23 (13) 2900-2902
    Google Scholar
  • 05 Ewer M S, Vooletich M T, Durand J B, Woods M L, Davis J R, Valero V , et al . Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.  J Clin Oncol. 2005;  23 (31) 7820-7826
    Google Scholar
  • 06 Hochster H , Wasserheit C , Speyer J . Cardiotoxicity and cardioprotection during chemotherapy.  Curr Opin Oncol. 1995;  7 (4) 304-309
    Google Scholar
  • 07 Swain S M, Whaley F S, Ewer M S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.  Cancer. 2003;  97 (11) 2869-2879
    Google Scholar
  • 08 Dalen EC van , Pal HJ van der , Caron H N, Kremer L C. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2006(4): CD005008. 
    Google Scholar
  • 09 Ryberg M , Nielsen D , Cortese G , Nielsen G , Skovsgaard T , Andersen P K. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.  J Natl Cancer Inst. 2008;  100 (15) 1058-1067
    Google Scholar
  • 10 Minow R A, Benjamin R S, Lee E T, Gottlieb J A. Adriamycin cardiomyopathy--risk factors.  Cancer. 1977;  39 (4) 1397-1402
    CrossrefPubMedGoogle Scholar
  • 11 Jones S , Holmes F A, O'Shaughnessy J , Blum J L, Vukelja S J, McIntyre K J, et al . Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.  J Clin Oncol. 2009;  27 (8) 1177-1183
    CrossrefPubMedGoogle Scholar
  • 12 Carver J R, Schuster S J, Glick J H. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.  J Clin Oncol. 2008;  26 (19) 3122-3124
    CrossrefPubMedGoogle Scholar
  • 13 Gardinale D , Sandri M T, Colombo A , Colombo N , Boeri M , Lamantia G , et al . Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.  Circulation. 2004;  109 (22) 2749-2754
    CrossrefPubMedGoogle Scholar
  • 14 Dalen EC van , Michiels E M, Caron H N, Kremer L C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006(4): CD005006. 
    PubMedGoogle Scholar
  • 15 Orditura M , Quaglia F , Morgillo F , Martinelli E , Lieto E , De Rosa G , et al . Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).  Oncol Rep. 2004;  12 (3) 549-556
    PubMedGoogle Scholar
  • 16 Anton A , Ruiz A , Segui M A, Calvo L , Munoz M , Lao J , et al . Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.  Ann Oncol. 2009;  20 (3) 454-459
    CrossrefPubMedGoogle Scholar
  • 17 Hasinoff B B, Hellmann K , Herman E H, Ferrans V J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.  Curr Med Chem. 1998;  5 (1) 1-28
    PubMedGoogle Scholar
  • 18 Dalen EC van , Caron H N, Dickinson H O, Kremer L C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005(1): CD003917. 
    PubMedGoogle Scholar
  • 19 Dalen EC van , Caron H N, Dickinson H O, Kremer L C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008(2): CD003917. 
    PubMedGoogle Scholar
  • 20 Swain S M, Wahley F S, Gerber M C, Weisberg S , York M , Spicer D , et al . Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.  J Clin Oncol. 1997;  15 (4) 1318-1332
    PubMedGoogle Scholar
  • 21 Tebbi C K, London W B, Friedman D , Villaluna D , De Alarcon P A, Constine L S, et al . Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.  J Clin Oncol. 2007;  25 (5) 493-500
    CrossrefPubMedGoogle Scholar
  • 22 Hensley M L, Hagerty K L, Kewalramani T , Green D M, Meropol N J, Wasserman T H, et al . American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.  J Clin Oncol. 2009;  27 (1) 127-145
    CrossrefPubMedGoogle Scholar
  • 23 Lipshultz S E, Lipsitz S R, Mone S M, Goorin A M, Sallan S E, Sanders S P, et al . Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.  N Engl J Med. 1995;  332 (26) 1738-1743
    CrossrefPubMedGoogle Scholar
  • 24 Gardinale D , Colombo A , Sandri M T, Lamantia G , Colombo N , Civelli M , et al . Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.  Circulation. 2006;  114 (23) 2474-2481
    CrossrefPubMedGoogle Scholar
  • 25 Silber J H, Cnaan A , Clark B J, Paridon S M, Chin A J, Rychik J , et al . Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.  J Clin Oncol. 2004;  22 (5) 820-828
    CrossrefPubMedGoogle Scholar
  • 26 [Anonym]. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.  N Engl J Med. 1991;  325 (5) 293-302
    CrossrefPubMedGoogle Scholar
  • 27 Blanco J G, Leisenring W M, Gonzalez-Covarrubias V M, Kawashima T I, Davies S M, Relling M V, et al . Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.  Cancer. 2008;  112 (12) 2789-2795
    CrossrefPubMedGoogle Scholar
  • 28 Wojnowski L , Kulle B , Schirmer M , Schulter G , Schmidt A , Rosenberger A , et al . NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.  Circulation. 2005;  112 (24) 3754-3762
    CrossrefPubMedGoogle Scholar
  • 30 Chicco A J, Hydock D S, Schneider C M, Hayward R . Physical activity and survival after diagnosis of invasive breast cancer.  Cancer Epidemiol Biomarkers Prev. 2006;  100 (2) 519-527
    PubMedGoogle Scholar
  • 31 Wonders K Y, Hydock D S, Schneider C M, Hayward R . Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.  J Appl Physiol. 2008;  7 (3) 147-154
    PubMedGoogle Scholar
  • 32 Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A , McGuire WL  . Acute exercise protects against doxorubicin cardiotoxicity.  Integr Cancer Ther. 1987;  235 (4785) 117-182
    PubMedGoogle Scholar
  • 33 Piccart-Gebhart M J, Procter M , Leyland-Jones B , Goldhirsch A , Untch M , Smith I , et al . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.  Science. 2005;  353 (16) 1659-1672
    CrossrefPubMedGoogle Scholar
  • 34 Romond E H, Perez E A, Bryant J , Suman V J, Geyer Jr C E, Davidson N E, et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 (16) 1673-1684
    CrossrefPubMedGoogle Scholar
  • 35 Pritchard K I, Shepherd L E, O'Malley F P, Andrulis I L, Tu D , Bramwell V H, et al . HER2 and responsiveness of breast cancer to adjuvant chemotherapy.  N Engl J Med. 2006;  354 (20) 2103-2111
    CrossrefPubMedGoogle Scholar
  • 36 Tan-Chiu E , Yothers G , Romond E , Geyer Jr C E, Ewer M , Keefe D , et al . Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.  J Clin Oncol. 2005;  23 (31) 7811-7819
    CrossrefPubMedGoogle Scholar
  • 37 Seidman A , Hudis C , Pierri M K, Shak S , Paton V , Ashby M , et al . Cardiac dysfunction in the trastuzumab clinical trials experience.  J Clin Oncol. 2002;  20 (5) 1215-1221
    CrossrefPubMedGoogle Scholar
  • 38 Slamon D J, Leyland-Jones B , Shak S , Fuchs H , Paton V , Bajamonde A , et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med. 2001;  344 (11) 783-792
    CrossrefPubMedGoogle Scholar
  • 39 Telli M L, Hunt S A, Carlson R W, Guardino A E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.  J Clin Oncol. 2007;  25 (23) 3525-3533
    CrossrefPubMedGoogle Scholar
  • 40 Perez E A, Suman V J, Davidson N E, Kaufman P A, Martino S , Dakhil S R, et al . Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.  J Clin Oncol. 2004;  22 (18) 3700-3704
    CrossrefPubMedGoogle Scholar
  • 41 Garratt A N, Ozcelik C , Birchmeier C . ErbB2 pathways in heart and neural diseases.  Trends Cardiovasc Med. 2003;  13 (2) 80-86
    CrossrefPubMedGoogle Scholar
  • 42 Negro A , Brar B K, Lee K F. Essential roles of Her2/erbB2 in cardiac development and function.  Recent Prog Horm Res. 2004;  59 1-12
    CrossrefPubMedGoogle Scholar
  • 43 Crone S A, Zhao Y Y, Fan L , Gu Y , Minamisawa S , Liu Y , et al . ErbB2 is essential in the prevention of dilated cardiomyopathy.  Nat Med. 2002;  8 (5) 459-465
    CrossrefPubMedGoogle Scholar
  • 44 Grazette L P, Boecker W , Matsui T , Semigran M , Force T L, Hajjar R J, et al . Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.  J Am Coll Cardiol. 2004;  44 (11) 2231-2238
    CrossrefPubMedGoogle Scholar
  • 45 Suter T M, Cook-Bruns N , Barton C . Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.  Breast. 2004;  13 (3) 173-183
    CrossrefPubMedGoogle Scholar
  • 46 Guarneri V , Lenihan D J, Valero V , Durand J B, Broglio K , Hess K R, et al . Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.  J Clin Oncol. 2006;  24 (25) 4107-4115
    CrossrefPubMedGoogle Scholar
  • 47 Schumacher K , Gemke U , Fugunt R , Marmé A , Grischke E , Fehm T . Signifikante Kardiotoxizität unter Trastuzumab- Zwei Case Reports.  Senologie - Zeitschrift fÃŒr Mammadiagnostik und -therapie. 2008;  5 Abstract Nr. A 129
    PubMedGoogle Scholar
  • 48 [Anonym]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 (8934) 1383-1389
    PubMedGoogle Scholar
  • 49 Hoppe U C, Bohm M , Dietz R , Hanrath P , Kroemer H K, Osterspey A , et al . [Guidelines for therapy of chronic heart failure].  Z Kardiol. 2005;  94 (8) 488-509
    CrossrefPubMedGoogle Scholar
  • 50 Harris E E, Correa C , Hwang W T, Liao J , Litt H I, Ferrari V A, et al . Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.  J Clin Oncol. 2006;  24 (25) 4100-4106
    CrossrefPubMedGoogle Scholar
  • 51 Roychoudhuri R , Robinson D , Putcha V , Cuzick J , Darby S , Moller H  . Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study.  BMC Cancer. 2007;  7 9
    CrossrefPubMedGoogle Scholar
  • 52 Hooning M J, Botma A , Aleman B M, Baaijens M H, Bartelink H , Klijn J G, et al . Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.  J Natl Cancer Inst. 2007;  95 (5) 365-375
    PubMedGoogle Scholar
  • 53 Harris E E. Cardiac mortality and morbidity after breast cancer treatment.  Cancer Control. 2008;  15 (2) 120-129
    PubMedGoogle Scholar
  • 54 Grey A B, Stapleton J P, Evans M C, Reid I R. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.  J Clin Endocrinol Metab. 1995;  80 (11) 3191-3195
    CrossrefPubMedGoogle Scholar
  • 55 Coombes R C, Kilburn L S, Snowdon C E, Paridaens R , Coleman R E, Jones S E, et al . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 (9561) 559-570
    CrossrefPubMedGoogle Scholar
  • 56 Mouridsen H , Keshaviah A , Coates A S, Rabaglio M , Castiglione-Gertsch M , Sun Z , et al . Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.  J Clin Oncol. 2007;  25 (36) 5715-5722
    CrossrefPubMedGoogle Scholar
  • 57 Lenihan D J, Esteva F J. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.  Oncologist. 2008;  13 (12) 1224-1234
    CrossrefPubMedGoogle Scholar
  • 58 Ewer M S, Lenihan D J. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?.  Nat Clin Pract Oncol. 2008;  5 (4) 192-193
    CrossrefPubMedGoogle Scholar
  • 59 Jensen B V, Skovsgaard T , Nielsen S L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.  Ann Oncol. 2002;  13 (5) 669-709
    CrossrefPubMedGoogle Scholar
      >